FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2968584714> ?p ?o ?g. }

• W2968584714 endingPage "e1416" @default.
• W2968584714 startingPage "e1409" @default.
• W2968584714 abstract "Abstract Background This randomized, double-blinded, phase II trial evaluated the efficacy of carboplatin and pemetrexed plus either apatorsen, an antisense oligonucleotide targeting heat shock protein (Hsp) 27 mRNA, or placebo in patients with previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC). Methods Patients were randomized 1:1 to Arm A (carboplatin/pemetrexed plus apatorsen) or Arm B (carboplatin/pemetrexed plus placebo). Treatment was administered in 21-day cycles, with restaging every two cycles, until progression or intolerable toxicity. Serum Hsp27 levels were analyzed at baseline and during treatment. The primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS), objective response rate, and toxicity. Results The trial enrolled 155 patients (median age 66 years; 44% Eastern Cooperative Oncology Group performance status 0). Toxicities were similar in the 2 treatment arms; cytopenias, nausea, vomiting, and fatigue were the most frequent treatment-related adverse events. Median PFS and OS were 6.0 and 10.8 months, respectively, for Arm A, and 4.9 and 11.8 months for Arm B (differences not statistically significant). Overall response rates were 27% for Arm A and 32% for Arm B. Sixteen patients (12%) had high serum levels of Hsp27 at baseline. In this small group, patients who received apatorsen had median PFS of 10.8 months, and those who received placebo had median PFS 4.8 months. Conclusion The addition of apatorsen to carboplatin and pemetrexed was well tolerated but did not improve outcomes in patients with metastatic nonsquamous NSCLC cancer in the first-line setting. Implications for Practice This randomized, double-blinded, phase II trial evaluated the efficacy of carboplatin and pemetrexed plus either apatorsen, an antisense oligonucleotide targeting heat shock protein 27 mRNA, or placebo in patients with previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC). The addition of apatorsen to carboplatin and pemetrexed was well tolerated but did not improve outcomes in patients with metastatic nonsquamous NSCLC cancer in the first-line setting." @default.
• W2968584714 created "2019-08-22" @default.
• W2968584714 creator A5010727297 @default.
• W2968584714 creator A5018054038 @default.
• W2968584714 creator A5023257030 @default.
• W2968584714 creator A5025653253 @default.
• W2968584714 creator A5040180882 @default.
• W2968584714 creator A5053359739 @default.
• W2968584714 creator A5062468425 @default.
• W2968584714 creator A5065917441 @default.
• W2968584714 creator A5071319691 @default.
• W2968584714 creator A5072308451 @default.
• W2968584714 creator A5076017612 @default.
• W2968584714 creator A5076615101 @default.
• W2968584714 creator A5079398298 @default.
• W2968584714 creator A5087929151 @default.
• W2968584714 creator A5090068456 @default.
• W2968584714 date "2019-08-16" @default.
• W2968584714 modified "2023-09-27" @default.
• W2968584714 title "A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial" @default.
• W2968584714 cites W1835567984 @default.
• W2968584714 cites W2019607817 @default.
• W2968584714 cites W2034710772 @default.
• W2968584714 cites W2065179135 @default.
• W2968584714 cites W2072189442 @default.
• W2968584714 cites W2088565559 @default.
• W2968584714 cites W2106664438 @default.
• W2968584714 cites W2114788766 @default.
• W2968584714 cites W2119887420 @default.
• W2968584714 cites W2125007784 @default.
• W2968584714 cites W2168213980 @default.
• W2968584714 cites W2175415100 @default.
• W2968584714 cites W2334914145 @default.
• W2968584714 cites W2476879925 @default.
• W2968584714 cites W2570618306 @default.
• W2968584714 cites W2597648644 @default.
• W2968584714 cites W2757841320 @default.
• W2968584714 cites W2917837889 @default.
• W2968584714 cites W4245694191 @default.
• W2968584714 cites W4293241248 @default.
• W2968584714 doi "https://doi.org/10.1634/theoncologist.2018-0518" @default.
• W2968584714 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6975937" @default.
• W2968584714 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31420467" @default.
• W2968584714 hasPublicationYear "2019" @default.
• W2968584714 type Work @default.
• W2968584714 sameAs 2968584714 @default.
• W2968584714 citedByCount "23" @default.
• W2968584714 countsByYear W29685847142019 @default.
• W2968584714 countsByYear W29685847142020 @default.
• W2968584714 countsByYear W29685847142021 @default.
• W2968584714 countsByYear W29685847142022 @default.
• W2968584714 crossrefType "journal-article" @default.
• W2968584714 hasAuthorship W2968584714A5010727297 @default.
• W2968584714 hasAuthorship W2968584714A5018054038 @default.
• W2968584714 hasAuthorship W2968584714A5023257030 @default.
• W2968584714 hasAuthorship W2968584714A5025653253 @default.
• W2968584714 hasAuthorship W2968584714A5040180882 @default.
• W2968584714 hasAuthorship W2968584714A5053359739 @default.
• W2968584714 hasAuthorship W2968584714A5062468425 @default.
• W2968584714 hasAuthorship W2968584714A5065917441 @default.
• W2968584714 hasAuthorship W2968584714A5071319691 @default.
• W2968584714 hasAuthorship W2968584714A5072308451 @default.
• W2968584714 hasAuthorship W2968584714A5076017612 @default.
• W2968584714 hasAuthorship W2968584714A5076615101 @default.
• W2968584714 hasAuthorship W2968584714A5079398298 @default.
• W2968584714 hasAuthorship W2968584714A5087929151 @default.
• W2968584714 hasAuthorship W2968584714A5090068456 @default.
• W2968584714 hasBestOaLocation W29685847141 @default.
• W2968584714 hasConcept C126322002 @default.
• W2968584714 hasConcept C141071460 @default.
• W2968584714 hasConcept C142724271 @default.
• W2968584714 hasConcept C143998085 @default.
• W2968584714 hasConcept C168563851 @default.
• W2968584714 hasConcept C197934379 @default.
• W2968584714 hasConcept C203092338 @default.
• W2968584714 hasConcept C204787440 @default.
• W2968584714 hasConcept C27081682 @default.
• W2968584714 hasConcept C2776256026 @default.
• W2968584714 hasConcept C2776694085 @default.
• W2968584714 hasConcept C2777240266 @default.
• W2968584714 hasConcept C2778239845 @default.
• W2968584714 hasConcept C2780580376 @default.
• W2968584714 hasConcept C2781451048 @default.
• W2968584714 hasConcept C31760486 @default.
• W2968584714 hasConcept C71924100 @default.
• W2968584714 hasConceptScore W2968584714C126322002 @default.
• W2968584714 hasConceptScore W2968584714C141071460 @default.
• W2968584714 hasConceptScore W2968584714C142724271 @default.
• W2968584714 hasConceptScore W2968584714C143998085 @default.
• W2968584714 hasConceptScore W2968584714C168563851 @default.
• W2968584714 hasConceptScore W2968584714C197934379 @default.
• W2968584714 hasConceptScore W2968584714C203092338 @default.
• W2968584714 hasConceptScore W2968584714C204787440 @default.
• W2968584714 hasConceptScore W2968584714C27081682 @default.
• W2968584714 hasConceptScore W2968584714C2776256026 @default.
• W2968584714 hasConceptScore W2968584714C2776694085 @default.
• W2968584714 hasConceptScore W2968584714C2777240266 @default.
• W2968584714 hasConceptScore W2968584714C2778239845 @default.

• next